Acadia Pharmaceuticals (ACAD) Cash from Investing Activities (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Cash from Investing Activities of $66.3 million for Q1 2026, up 153.43% year-over-year from $26.2 million in Q1 2025, and up 218.64% quarter-over-quarter from -$55.9 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $66.3 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 153.43% year-over-year to $66.3 million; the TTM figure through Mar 2026 stood at -$112.2 million (up 20.15% YoY), while the FY2025 annual figure was -$302.6 million, down 890.78% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $66.3 million, up from -$55.9 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $192.5 million in Q1 2023, with the low at -$194.3 million in Q2 2023.
- The 5-year median for Cash from Investing Activities is -$17.7 million (2022), against an average of -$9.5 million.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities surged 35301.73% in 2024, then slumped 783.6% in 2025.
- Acadia Pharmaceuticals' Cash from Investing Activities stood at -$17.7 million in 2022, then soared by 98.04% to -$347000.0 in 2023, then soared by 35301.73% to $122.2 million in 2024, then sank by 145.74% to -$55.9 million in 2025, then surged by 218.64% to $66.3 million in 2026.
- Business Quant data shows ACAD's Cash from Investing Activities at $66.3 million in Q1 2026, -$55.9 million in Q4 2025, and -$79.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | -8.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.53 Mn |
| Jun 30, 2026 | -8.53 Mn |
| Mar 31, 2026 | 66.28 Mn |
| Mar 31, 2026 | 66.28 Mn |
| Dec 31, 2025 | -55.87 Mn |
| Dec 31, 2025 | -55.87 Mn |
| Sep 30, 2025 | -79.35 Mn |
| Sep 30, 2025 | -79.35 Mn |
| Jun 30, 2025 | -43.29 Mn |
| Jun 30, 2025 | -43.29 Mn |
| Mar 31, 2025 | -124.05 Mn |
| Mar 31, 2025 | -124.05 Mn |
| Dec 31, 2024 | 122.15 Mn |
| Dec 31, 2024 | 122.15 Mn |
| Sep 30, 2024 | -82.46 Mn |
| Sep 30, 2024 | -82.46 Mn |
| Jun 30, 2024 | -56.19 Mn |
| Jun 30, 2024 | -56.19 Mn |
| Mar 31, 2024 | -14.04 Mn |
| Mar 31, 2024 | -14.04 Mn |